Drugs / NKTR-262
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03435640 | Mar 2018 → May 2022 | colorectal cancer, cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma, melanoma +3 | Nektar Therapeutics | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKTR-262 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03435640 ↗ |
| Action | Activate | “NKTR-262 is a small molecule agonist of toll-like receptors (TLRs) 7/8” NCT03435640 ↗ |
| Modality | Small molecule | “NKTR-262 is a small molecule agonist of toll-like receptors (TLRs) 7/8” NCT03435640 ↗ |
| Route | Other | “intratumoral (IT) injections of NKTR-262” NCT03435640 ↗ |
| Target | TLR7 | “NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity” PMID 35444059 ↗ Apr 2022 |